Here's What to Expect From Medtronic's Next Earnings Report
/Medtronic%20Plc%20HQ-by%20JHVEPhoto%20via%20iStock.jpg)
Galway, Ireland-based Medtronic plc (MDT) designs, manufactures, and distributes a wide range of medical devices, therapies, and digital health solutions used to treat chronic and complex health conditions across global healthcare systems. Valued at a market cap of $118 billion, the company is committed to advancing medical technology to alleviate pain, restore health, and extend life. It is scheduled to announce its fiscal Q1 earnings for 2026 before the market opens on Tuesday, Aug. 19.
Before this event, analysts project this healthcare giant to report a profit of $1.23 per share, in line with the year-ago quarter. The company has surpassed Wall Street’s bottom-line estimates in each of the last four quarters. Its earnings of $1.62 per share in the previous quarter outpaced the consensus estimates by 2.5%.
For the full year, analysts expect MDT to report EPS of $5.55, up 1.1% from $5.49 per share in fiscal 2025. Furthermore, its EPS is expected to grow 7.9% year-over-year to $5.99 in fiscal 2027.
MDT has rallied 15.9% over the past 52 weeks, outpacing both the S&P 500 Index's ($SPX) 14.5% uptick and the Health Care Select Sector SPDR Fund’s (XLV) 8.3% drop over the same time frame.
Despite delivering stronger-than-expected results, shares of Medtronic plunged 2.3% after its Q4 earnings release on May 21. The company’s revenue improved 3.9% year-over-year to $8.9 billion, topping consensus estimates by 1.1%. Moreover, its adjusted EPS of $1.62 advanced nearly 11% from the year-ago quarter and came in 2.5% above the analyst expectations. Looking ahead to fiscal 2026, Medtronic expects adjusted EPS in the range of $5.50 to $5.60, and anticipates organic sales growth of approximately 5%.
Wall Street analysts are moderately optimistic about MDT’s stock, with an overall "Moderate Buy" rating. Among 30 analysts covering the stock, 13 recommend "Strong Buy," one indicates a "Moderate Buy," 15 advise “Hold,” and one suggests a "Strong Sell” rating. The mean price target for Medtronic is $95.83, implying a 4.2% premium from the current levels.
On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.